Differences in epidemiology of enteropathogens in children pre- and post-rotavirus vaccine introduction in Kilifi, coastal Kenya.
Children
Co-infections
Enteropathogens
Epidemiology
Kenya
RVA
Taqman array card
Vaccination
Journal
Gut pathogens
ISSN: 1757-4749
Titre abrégé: Gut Pathog
Pays: England
ID NLM: 101474263
Informations de publication
Date de publication:
01 Aug 2022
01 Aug 2022
Historique:
received:
06
05
2022
accepted:
18
07
2022
entrez:
1
8
2022
pubmed:
2
8
2022
medline:
2
8
2022
Statut:
epublish
Résumé
Kenya introduced Rotarix We used a custom TaqMan Array Card (TAC) to screen for 28 different enteropathogens in 718 stools from children aged less than 13 years admitted to Kilifi County Hospital, coastal Kenya, following presentation with diarrhea in 2013 (before vaccine introduction) and in 2016-2018 (after vaccine introduction). Pathogen positivity rate differences between pre- and post-Rotarix In 665 specimens (92.6%), one or more enteropathogen was detected, while in 323 specimens (48.6%) three or more enteropathogens were detected. The top six detected enteropathogens were: enteroaggregative Escherichia coli (EAggEC; 42.1%), enteropathogenic Escherichia coli (EPEC; 30.2%), enterovirus (26.9%), rotavirus group A (RVA; 24.8%), parechovirus (16.6%) and norovirus GI/GII (14.4%). Post-rotavirus vaccine introduction, there was a significant increase in the proportion of samples testing positive for EAggEC (35.7% vs. 45.3%, p = 0.014), cytomegalovirus (4.2% vs. 9.9%, p = 0.008), Vibrio cholerae (0.0% vs. 2.3%, p = 0.019), Strongyloides species (0.8% vs. 3.6%, p = 0.048) and Dientamoeba fragilis (2.1% vs. 7.8%, p = 0.004). Although not reaching statistical significance, the positivity rate of adenovirus 40/41 (5.8% vs. 7.3%, p = 0.444), norovirus GI/GII (11.2% vs. 15.9%, p = 0.089), Shigella species (8.7% vs. 13.0%, p = 0.092) and Cryptosporidium spp. (11.6% vs. 14.7%, p = 0.261) appeared to increase post-vaccine introduction. Conversely, the positivity rate of sapovirus decreased significantly post-vaccine introduction (7.8% vs. 4.0%, p = 0.030) while that of RVA appeared not to change (27.4% vs. 23.5%, p = 0.253). More enteropathogen coinfections were detected per child post-vaccine introduction compared to before (mean: 2.7 vs. 2.3; p = 0.0025). In this rural Coastal Kenya setting, childhood enteropathogen infection burden was high both pre- and post-rotavirus vaccination introduction. Children who had diarrheal admissions post-vaccination showed an increase in coinfections and changes in specific enteropathogen positivity rates. This study highlights the utility of multipathogen detection platforms such as TAC in understanding etiology of childhood acute gastroenteritis in resource-limited regions.
Sections du résumé
BACKGROUND
BACKGROUND
Kenya introduced Rotarix
METHODS
METHODS
We used a custom TaqMan Array Card (TAC) to screen for 28 different enteropathogens in 718 stools from children aged less than 13 years admitted to Kilifi County Hospital, coastal Kenya, following presentation with diarrhea in 2013 (before vaccine introduction) and in 2016-2018 (after vaccine introduction). Pathogen positivity rate differences between pre- and post-Rotarix
RESULTS
RESULTS
In 665 specimens (92.6%), one or more enteropathogen was detected, while in 323 specimens (48.6%) three or more enteropathogens were detected. The top six detected enteropathogens were: enteroaggregative Escherichia coli (EAggEC; 42.1%), enteropathogenic Escherichia coli (EPEC; 30.2%), enterovirus (26.9%), rotavirus group A (RVA; 24.8%), parechovirus (16.6%) and norovirus GI/GII (14.4%). Post-rotavirus vaccine introduction, there was a significant increase in the proportion of samples testing positive for EAggEC (35.7% vs. 45.3%, p = 0.014), cytomegalovirus (4.2% vs. 9.9%, p = 0.008), Vibrio cholerae (0.0% vs. 2.3%, p = 0.019), Strongyloides species (0.8% vs. 3.6%, p = 0.048) and Dientamoeba fragilis (2.1% vs. 7.8%, p = 0.004). Although not reaching statistical significance, the positivity rate of adenovirus 40/41 (5.8% vs. 7.3%, p = 0.444), norovirus GI/GII (11.2% vs. 15.9%, p = 0.089), Shigella species (8.7% vs. 13.0%, p = 0.092) and Cryptosporidium spp. (11.6% vs. 14.7%, p = 0.261) appeared to increase post-vaccine introduction. Conversely, the positivity rate of sapovirus decreased significantly post-vaccine introduction (7.8% vs. 4.0%, p = 0.030) while that of RVA appeared not to change (27.4% vs. 23.5%, p = 0.253). More enteropathogen coinfections were detected per child post-vaccine introduction compared to before (mean: 2.7 vs. 2.3; p = 0.0025).
CONCLUSIONS
CONCLUSIONS
In this rural Coastal Kenya setting, childhood enteropathogen infection burden was high both pre- and post-rotavirus vaccination introduction. Children who had diarrheal admissions post-vaccination showed an increase in coinfections and changes in specific enteropathogen positivity rates. This study highlights the utility of multipathogen detection platforms such as TAC in understanding etiology of childhood acute gastroenteritis in resource-limited regions.
Identifiants
pubmed: 35915480
doi: 10.1186/s13099-022-00506-z
pii: 10.1186/s13099-022-00506-z
pmc: PMC9340678
doi:
Types de publication
Journal Article
Langues
eng
Pagination
32Subventions
Organisme : National Institutes for Health Research
ID : CDF-2011-04-017
Organisme : Wellcome Trust
ID : 102975
Pays : United Kingdom
Organisme : DELTAS Africa Initiative
ID : DEL-15-003
Organisme : Cambridge Biomedical Research Center, the Economic and Social Science Research Council
ID : AH/R001952/1
Organisme : Medical Research Council
ID : MR/S013164/1
Pays : United Kingdom
Organisme : EPA
ID : EP-C-15-003
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom
Informations de copyright
© 2022. The Author(s).
Références
Clin Infect Dis. 2020 May 23;70(11):2306-2313
pubmed: 31544211
Lancet Glob Health. 2018 Dec;6(12):e1309-e1318
pubmed: 30287127
J Korean Med Sci. 2021 Jun 21;36(24):e180
pubmed: 34155841
Pathogens. 2020 Aug 15;9(8):
pubmed: 32824245
Lancet Glob Health. 2019 Jul;7(7):e961-e967
pubmed: 31129126
BMC Infect Dis. 2016 Sep 06;16:477
pubmed: 27600526
Lancet. 2008 Jan 26;371(9609):301-2
pubmed: 18294994
Am J Trop Med Hyg. 2017 Dec;97(6):1872-1875
pubmed: 29016338
MethodsX. 2022 Apr 20;9:101707
pubmed: 35518918
Hum Vaccin Immunother. 2019;15(6):1215-1227
pubmed: 30735087
J Appl Microbiol. 2012 Nov;113(5):1014-26
pubmed: 22747964
Vaccine X. 2019 Jan 04;1:100005
pubmed: 31384727
Open Forum Infect Dis. 2018 Nov 12;5(11):ofy292
pubmed: 30539038
Lancet Infect Dis. 2018 Nov;18(11):1211-1228
pubmed: 30243583
Vaccine. 2017 Sep 12;35(38):5217-5223
pubmed: 28780116
BMC Med. 2019 Jan 28;17(1):20
pubmed: 30686268
Epidemiol Mikrobiol Imunol. 2018 Winter;67(3):110-113
pubmed: 30602277
Trop Med Int Health. 2022 Jun 14;:
pubmed: 35700209
BMC Infect Dis. 2021 Jan 6;21(1):7
pubmed: 33407198
J Infect Dis. 2017 Jul 15;216(2):220-227
pubmed: 28838152
J Infect Chemother. 2021 Apr;27(4):598-603
pubmed: 33386258
Cochrane Database Syst Rev. 2012 Nov 14;11:CD008521
pubmed: 23152260
Viruses. 2021 Nov 30;13(12):
pubmed: 34960668
BMC Infect Dis. 2019 Jan 11;19(1):47
pubmed: 30634922
Int J Epidemiol. 2012 Jun;41(3):650-7
pubmed: 22544844
Scand J Infect Dis. 1990;22(3):259-67
pubmed: 2371542
BMC Infect Dis. 2016 Jun 14;16:287
pubmed: 27296987
Trans R Soc Trop Med Hyg. 2013 Feb;107(2):83-90
pubmed: 23222955
Curr Infect Dis Rep. 2020 Jan 28;22(2):4
pubmed: 31993758
Gut Pathog. 2021 May 24;13(1):33
pubmed: 34030738
PLoS One. 2016 Nov 9;11(11):e0165282
pubmed: 27828987
PLoS Negl Trop Dis. 2017 Jul 24;11(7):e0005798
pubmed: 28742106
MMWR Morb Mortal Wkly Rep. 2018 Aug 31;67(34):958-961
pubmed: 30161101
Clin Infect Dis. 2017 Oct 1;65(7):1144-1151
pubmed: 28575304
Microbiol Spectr. 2022 Jun 29;10(3):e0266921
pubmed: 35638853
Lancet. 2016 Sep 24;388(10051):1291-301
pubmed: 27673470
Virus Evol. 2021 Mar 12;7(1):veab023
pubmed: 34522389
J Infect Dis. 2020 Nov 13;222(12):2035-2040
pubmed: 31834930
Open Forum Infect Dis. 2021 Nov 24;8(12):ofab592
pubmed: 34988246
Clin Infect Dis. 2016 May 1;62 Suppl 2:S213-9
pubmed: 27059359
Lancet Glob Health. 2019 May;7(5):e568-e584
pubmed: 31000128
J Med Virol. 2004 May;73(1):118-22
pubmed: 15042658
Pediatrics. 2022 Jan 1;149(1):
pubmed: 34918158
Curr Opin Pediatr. 2016 Feb;28(1):107-13
pubmed: 26709690
J Clin Microbiol. 2013 Feb;51(2):472-80
pubmed: 23175269
BMC Infect Dis. 2020 Jul 13;20(1):504
pubmed: 32660437
Wellcome Open Res. 2020 Aug 6;5:187
pubmed: 33215049
J Infect Dis. 2019 Jun 19;220(2):213-218
pubmed: 30816414
Clin Infect Dis. 2020 May 23;70(11):2298-2305
pubmed: 31326980
Lancet Glob Health. 2018 Dec;6(12):e1319-e1328
pubmed: 30287125
Vaccines (Basel). 2022 Feb 23;10(3):
pubmed: 35334978
Int J Epidemiol. 2017 Jun 1;46(3):792-792h
pubmed: 27789669